Allurion Technologies (NYSE:ALUR) Lifted to “Strong-Buy” at Roth Capital

Allurion Technologies (NYSE:ALUR) was upgraded by stock analysts at Roth Capital to a “strong-buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Roth Mkm assumed coverage on shares of Allurion Technologies in a research report on Friday. They set a “buy” rating and a $2.00 price objective for the company. Chardan Capital lowered their price target on shares of Allurion Technologies from $5.00 to $2.50 and set a “buy” rating for the company in a report on Thursday, August 22nd.

Allurion Technologies Stock Performance

ALUR opened at $0.60 on Friday. Allurion Technologies has a 52-week low of $0.56 and a 52-week high of $6.43. The firm has a market cap of $28.53 million, a P/E ratio of -0.16 and a beta of -0.33. The business’s fifty day moving average is $0.84 and its 200-day moving average is $1.64.

Allurion Technologies (NYSE:ALUR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $11.77 million for the quarter. On average, research analysts predict that Allurion Technologies will post -0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Allurion Technologies stock. Accredited Investors Inc. boosted its holdings in Allurion Technologies Inc. (NYSE:ALUR) by 33.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 50,000 shares of the company’s stock after purchasing an additional 12,500 shares during the quarter. Accredited Investors Inc. owned about 0.10% of Allurion Technologies worth $50,000 at the end of the most recent quarter. 21.39% of the stock is owned by institutional investors.

About Allurion Technologies

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.